Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN3D72)

• Drug Name: SL-172154 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMN3D72

Molecule-Related Drug Atlas

Drug(s) Targeting CD40L receptor (CD40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[3]
APX005M	DMX2P5G	Melanoma	2C30	Phase 2	[4]
ASKP-1240	DM1CLKO	Transplant rejection	NE84	Phase 2	[5]
CFZ533	DM1TWIE	Graves disease	5A02.0	Phase 2	[3]
Dazodalibep	DM7YII9	Kidney transplant rejection	NE84	Phase 2	[6]
Iscalimab	DMW4CR8	Type-1 diabetes	5A10	Phase 2	[7]
KPL-404	DMQJODL	Rheumatoid arthritis	FA20	Phase 2	[8]
AT-1501	DMQIA5K	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[9]
Frexalimab	DMMJTYP	Multiple sclerosis	8A40	Phase 2	[10]
GEN1042	DMNP6T3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

Drug(s) Targeting Leukocyte surface antigen CD47 (CD47)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hu5F9-G4	DMBER0Q	Myelodysplastic syndrome	2A37	Phase 3	[12]
Evorpacept	DMJTX7Q	Gastric cancer	2B72	Phase 2/3	[13]
PF-07901801	DMEVYHR	Diffuse large B-cell lymphoma	2A81	Phase 2	[14]
ALX148	DMGQX0U	Myelodysplastic syndrome	2A37	Phase 1/2	[12]
DSP-107	DM8K0PR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[15]
AO-176	DMXU98C	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]
TG-1801	DM3K4FY	B-cell lymphoma	2A86	Phase 1	[17]
TTI-621	DMDNPAV	Haematological malignancy	2B33.Y	Phase 1	[18]
TTI-622	DMOCQ4K	Lymphoma	2A80-2A86	Phase 1	[19]
IBI188	DMXUJ1P	Myelodysplastic syndrome	2A37	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Inhibitor	[2]
Leukocyte surface antigen CD47 (CD47)	TT28S46	CD47_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04406623) Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Shattuck Labs.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
• [6] The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.
• [7] Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.
• [8] Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5.
• [9] ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
• [10] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Genmab.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
• [14] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of KAHR Medical.
• [16] Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
• [17] Clinical pipeline report, company report or official report of TG Theraputics.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Clinical pipeline report, company report or official report of Trillium Therapeutics.
• [20] Clinical pipeline report, company report or official report of Innovent Biologics.